T1-DISCO

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes.

A solid, uniform light blue color fills the entire image without any patterns, objects, or text visible.

Study Description

IRB #

CO-MIRB: 22-0794

NCT #

NCT04334707

Principal Investigator

Petter Bjornstad, MD

Study Location

UW Medicine Diabetes Institute

This is a double-blinded placebo trial planning to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. Participants will give themselves weekly injections of semaglutide (or placebo) for 8 months. Before starting and after completing the treatment, participants will have a procedure testing kidney function and insulin sensitivity that involves two IVs being placed. A torso MRI, echocardiogram, and DEXA scan will also be performed for cardiovascular function and body composition. Participants will come in four times while receiving treatment to monitor blood tests and side effects.

Study Details

FAQ T1-DISCO

Learn more about how you can contribute to important research by volunteering for T1-DISCO

Who Can Participate?

Individuals diagnosed with Type 1 Diabetes that are between the ages of 18 and 49, on an insulin pump, already wear or are willing to wear a CGM, and are not taking non-insulin diabetes medications (i.e. metformin, GLP-1s).

Compensation Provided

You will be paid for your time. If you complete all study visits, you will be paid $1,260.00

Contact Study Team

Interested? Complete Form Below to Contact Study Team

Contact Name: Amanda Bard

Phone Number: 504-521-7822

Email abard@uw.edu

Contact the Study Team - T1-DISCO

Name(Required)

First Last

Phone(Required)

Email(Required)

Enter Email Confirm Email

Comments(Required)

Preferred Method of Contact (email, phone call, text)